Organon & Co. $OGN Shares Bought by Jump Financial LLC

Jump Financial LLC grew its holdings in Organon & Co. (NYSE:OGN) by 72.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,702 shares of the company’s stock after purchasing an additional 10,402 shares during the quarter. Jump Financial LLC’s holdings in Organon & Co. were worth $368,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. SBI Securities Co. Ltd. lifted its stake in Organon & Co. by 17.6% in the 1st quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company’s stock worth $114,000 after purchasing an additional 1,145 shares in the last quarter. Rafferty Asset Management LLC lifted its stake in Organon & Co. by 5.6% in the 4th quarter. Rafferty Asset Management LLC now owns 22,627 shares of the company’s stock worth $338,000 after purchasing an additional 1,194 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Organon & Co. by 1.5% in the 1st quarter. Handelsbanken Fonder AB now owns 81,565 shares of the company’s stock worth $1,215,000 after purchasing an additional 1,200 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Organon & Co. by 13.9% in the 4th quarter. Hsbc Holdings PLC now owns 13,922 shares of the company’s stock worth $208,000 after purchasing an additional 1,703 shares in the last quarter. Finally, Xponance Inc. lifted its stake in Organon & Co. by 15.2% in the 1st quarter. Xponance Inc. now owns 13,828 shares of the company’s stock worth $206,000 after purchasing an additional 1,823 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Down 0.2%

Organon & Co. stock opened at $9.41 on Wednesday. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $22.42. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The firm has a 50 day moving average price of $9.59 and a 200 day moving average price of $11.14. The company has a market capitalization of $2.45 billion, a PE ratio of 3.50, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. During the same quarter last year, the firm earned $1.12 EPS. The firm’s revenue for the quarter was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. Research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Investors of record on Friday, August 15th will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 15th. Organon & Co.’s dividend payout ratio (DPR) is 2.97%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on OGN shares. Piper Sandler decreased their target price on shares of Organon & Co. from $24.00 to $18.00 and set an “overweight” rating on the stock in a research note on Thursday, May 15th. BNP Paribas raised shares of Organon & Co. to a “strong-buy” rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.